Key facts
- This page summarizes Kevin Robert Lind's Form 4 filing for Longboard Pharmaceuticals, Inc..
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Nov 2024, 20:48.
Kevin Robert Lind - 13 Nov 2024 Form 4 Insider Report for Longboard Pharmaceuticals, Inc.
- Reporting relationship
- CEO, Director
- Issuer ticker
- N/A
- Reported as of
- 13 Nov 2024
- Net transaction value
- +$40,002
- SEC form
- 4
- Accepted by SEC
- 13 Nov 2024, 20:48:14 UTC
- Prior SEC filing
- 29 Oct 2024
- Next SEC filing
- 02 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew J. Cronauer, Attorney-In-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin Robert Lind filed Form 4 for Longboard Pharmaceuticals, Inc. on 13 Nov 2024.
Change
- Previous filing in this sequence was filed on 29 Oct 2024.
- Current net transaction value: +$40,002.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LBPH
transaction
Common Stock
Options Exercise
- Transaction value
- $40,002
- Shares
- +12,808
- Change %
- +3%
- Price
- $3.12
- Shares after
- 443,740
- Date
- 13 Nov 2024
- Ownership
- Direct
- Footnotes
- F1
LBPH
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- -80,000
- Change %
- -18%
- Price
- $0.000000
- Shares after
- 363,740
- Date
- 13 Nov 2024
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LBPH
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -12,808
- Change %
- -4.8%
- Price
- $0.000000
- Shares after
- 255,377
- Date
- 13 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,808
- Exercise price
- $3.12
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents a cash exercise of vested stock options without a subsequent sale of the underlying shares of common stock.
Footnote F2
Represents shares of common stock gifted to a donor-advised trust.
Footnote F3
The shares subject to the stock option vested and became exercisable in 24 equal monthly installments commencing November 27, 2022.